Sign in
Taking people in United StatesPhase 3

Ulixacaltamide compared with placebo for essential tremor in adults

Tests ulixacaltamide against placebo in adults with essential tremor.

Key facts

Who runs it
Praxis Precision Medicines
Where
Morgantown, United StatesSee the site
Trial code
Registry title
Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)
Status
Recruiting
Phase
Phase 3
People taking part
1,000 people, planned
Started
2 Nov 2023
Expected to end
Mar 2027
Type of study
Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • 60 mg ulixacaltamide
  • Placebo
Record updated
6 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with essential tremor, a shaking of the hands when holding a position or moving. It compares ulixacaltamide with placebo, followed by a long-term study.

Age
18 Years to 85 Years
Sex
All sexes can join.
Disease stage
A doctor's diagnosis of essential tremor with tremor when holding a posture and when moving, confirmed by a central reviewer. In the main studies, body mass index (BMI) must be ≥18 kg/m2.
Earlier treatment
In the main studies, people can take at most 1 tremor medicine, at a stable dose for at least 1 month. No primidone within 2 weeks before screening. People cannot join if they had focused ultrasound or brain surgery for tremor, such as DBS or thalamotomy. No botulinum toxin for tremor in the 6 months before screening. No other trial drug within 30 days.

Main reasons for not taking part

  • Another condition that can cause tremor, such as Parkinson's disease, stroke or multiple sclerosis, or tremor on one side only
  • Pregnancy, breastfeeding, or plans to become pregnant
  • HIV, hepatitis B or hepatitis C infection
  • Substance use disorder, uncontrolled major psychiatric disorder, or past suicide attempt
  • Cancer in the past 5 years, long QT heart rhythm problem, or poor liver or kidney test results

The registry criteria, word for word

Show all 51 criteriaShow less

Who can take part

  • Has a body mass index (BMI) at Screening of ≥18 kg/m2
  • Has a clinical diagnosis of ET confirmed during screening and characterized by postural and action tremor
  • If currently receiving medication prescribed for ET, must be on ≤1 medications, on stable dose(s) for at least 1 month prior to Screening, and willing to maintain stable dose(s) throughout the study. As needed (PRN) use of prescribed ET medicines is not allowed with the exception of propranolol PRN. Participants prescribed propranolol PRN are eligible but must discontinue the PRN dose after the first day of screening. Primidone use is not allowed within 2 weeks prior to screening and throughout duration of study
  • Women of childbearing potential must undertake pregnancy tests, with a documented negative serum pregnancy test at Screening, negative urine pregnancy tests at Baseline (Day 1) prior to administration of study drug, throughout the intervention periods (as outlined in the SoA) and at the SFU or ED Visit, as appropriate
  • Is willing and able to use contraception as defined in the protocol and ICF
  • Has been assessed as an appropriate and suitable candidate by investigator and has a neurological exam and medical record(s) consistent with ET diagnosis, as confirmed by the ERC central reviewer
  • Confirm key inclusion criteria at Baseline
  • Has a clinical diagnosis of ET confirmed during screening and characterized by postural and action tremor
  • Women of childbearing potential must undertake pregnancy tests, with a documented negative serum pregnancy test at Screening, negative urine pregnancy tests prior to administration of study drug, throughout the intervention periods (as outlined in the SoA) and at the SFU or ED Visit, as appropriate
  • Is willing and able to use contraception
  • Has been assessed as an appropriate and suitable candidate by investigator and has a neurological exam and medical record(s) consistent with ET diagnosis, as confirmed by the ERC central reviewer

Who cannot take part

  • Is unwilling or unable to refrain from episodic use of medication(s)/substance(s) that might interfere with the evaluation of tremor during the study
  • Is sporadically using a benzodiazepine, sleep medication or anxiolytic (as further defined in the protocol), that in the judgement of the investigator or sponsor would confound the assessment of tremor
  • Has had prior magnetic resonance-guided focused ultrasound or surgical intervention for ET such as a deep brain stimulator (DBS) or lesion therapy such as thalamotomy
  • Has had botulinum toxin injection for ET in the 6 months prior to Screening or throughout the study
  • Is using the Cala trio health device for ET in 14 days prior to Screening or throughout the study
  • Has a history of substance use disorder consistent with Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revision (DSM-5-TR) criteria. Participants with a previous diagnosis of substance use disorder who have been in remission for at least 2 years can participate in the study
  • Is currently pregnant or breastfeeding or is planning to become pregnant during the clinical trial or within 31 days of the last study drug dose
  • Is currently taking a prescription or non-prescription product(s) and food known to be moderate or strong inhibitors or strong inducers (moderate inducers are not prohibited) of cytochrome P450 (CYP3A4), which cannot be discontinued at least 5 half-lives or 14 days prior (whichever is the longer period of time) to Baseline and withheld throughout the clinical study
  • Has received any experimental or investigational drug, device, or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening
  • Has a lifetime history of any suicide attempt, or suicidal ideation with intent within the past 2 years prior to Screening
  • Prior participation in an ulixacaltamide clinical trial at any time or other clinical trial evaluating a potential drug for ET in the past 6 months (with the exception of participants with documentation that they received placebo treatment only), with the exception of participants that are currently enrolled in and complete the EOT visit in PRAX-944-222 extension period
  • Has a history of substance use disorder consistent with Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revision (DSM-5-TR) criteria. Participants with a previous diagnosis of substance use disorder who have been in remission for at least 2 years can participate in the trial
  • Is currently pregnant or breastfeeding or is planning to become pregnant during the clinical trial or within 31 days of the last study drug dose
  • Has received any experimental or investigational drug, device, or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening
  • Has a lifetime history of any suicide attempt, or suicidal ideation with intent within the past 2 years prior to Screening
  • Participant has a positive drug screening associated with drug abuse or misuse
  • Has a known hypersensitivity to any component of the formulation of ulixacaltamide
  • Has a history of unilateral tremor or clinical evidence of another medical, neurological, or psychiatric condition that may explain or cause tremor, including but not limited to Parkinson's disease, Huntington's disease, Alzheimer's disease, stroke with neurologic sequelae, intention tremor (IT) caused by etiology other than ET, cerebellar disease (including spinocerebellar ataxias), primary dystonia, Fragile X Tremor/Ataxia syndrome or family history of Fragile X syndrome, traumatic brain injury, psychogenic tremor, alcohol or benzodiazepine abuse or withdrawal, multiple sclerosis, polyneuropathy (diabetic neuropathy allowed if disease does not affect gait or balance and does not involve upper extremity), and endocrine states such as uncontrolled or inadequately treated hypothyroidism, food, or supplement induced movement disorders (e.g., tremor related to beta agonists or caffeine), or other medical, neurological, or psychiatric conditions that may explain or cause tremor
  • History of human immunodeficiency virus (HIV) infection or positive screening result for: HIV 1 or 2 antibodies, hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (HCVAb)
  • Any major psychiatric disorder, including but not limited to depression and anxiety, that is uncontrolled (for the past 90 days) or, in the investigator's judgment, can interfere with any of the study procedures
  • Participants who have a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years prior to screen are excluded; Exceptions:; Participants with completely excised non-melanoma skin cancer (such as basal cell carcinoma or squamous cell carcinoma) or cervical carcinoma in situ are permitted at any time; Participants with a history of other malignancies deemed cured by adequate treatment are also permitted at any time
  • Participant has a positive alcohol or drug screening (including cannabis and cannabis-derived products). The participant can be enrolled in the study, if they are willing to stop use of cannabis or cannabis-related products after the Screening Visit and have a negative cannabidiol (CBD) screen result at Baseline (Day 1). A positive amphetamine, benzodiazepine or opioid drug screening result could be allowed if it is determined that the result is a false positive (for example caused by another medication), or if the result is due to a documented prescribed medication (for example: benzodiazepine or opioid) that in the opinion of the investigator or sponsor designee, is prescribed for a medical condition that aligns with standard of care, is not associated with substance abuse and the investigator's assessment determines that the medical condition and medication dose is stable and expected to remain stable throughout the trial
  • History of or evidence of psychogenic tremor
  • Has a known hypersensitivity to any component of the formulation of the ulixacaltamide
  • Has a history of unilateral tremor or clinical evidence of another medical, neurological, or psychiatric condition that may explain or cause tremor
  • History of or active human immunodeficiency virus (HIV) infection or positive screening result for: HIV 1 or 2 antibodies. Evidence of active hepatitis B or hepatitis C infection
  • Any major psychiatric disorder, including but not limited to depression and anxiety, that is uncontrolled (for the past 90 days)
  • Participants who have a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years prior to screen are excluded
  • History of or evidence of psychogenic tremor
  • Has any of the following abnormal test results at Screening: a serum total bilirubin value >1.5×upper limit of normal (ULN); a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >2×ULN. As an exception, participants that present with elevated bilirubin in the absence of elevations in ALT or AST that fits the pattern of Gilbert's syndrome may be enrolled after discussion with the medical monitor and/or sponsor designee if their conjugated bilirubin is below the ULN
  • History of long QT syndrome and/or a Fridericia formula corrected QT interval (QTcF) interval >450 msec (males) or >460 msec (females) per electrocardiogram (ECG) done at Screening
  • Has any other significant disease or disorder including but not limited to uncontrolled seizure or epilepsy, diabetes, cardiovascular disease, renal disease, laboratory abnormalities, or environmental factor that, in the opinion of the investigator or sponsor designee, may either put the participant at risk due to participation in the clinical trial, may influence or confound the result of the clinical trial, or may affect the participant's ability to participate in the clinical trial. Uncontrolled epilepsy or seizure is exclusionary and is defined as a seizure or epilepsy diagnosed by a medical clinician and a documented seizure or change in seizure medication (medication or dose) in the last 2 years. An estimated glomerular filtration rate (eGFR) of <60 using the 2021 Chronic Kidney Disease-Epidemiology (CKD-EPI) formula mL/min/1.73m2 or urine albumin creatinine ratio (uACR) of ≥ 30 mg/g is exclusionary
  • Has any of the following abnormal test results at Screening: a serum total bilirubin value >1.5×upper limit of normal (ULN); a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >2×ULN
  • History of or currently comorbid long QT syndrome and/or a Fridericia formula corrected QT interval (QTcF)
  • Has any other significant disease or disorder including but not limited to uncontrolled seizure or epilepsy, diabetes, cardiovascular disease, renal disease, laboratory abnormalities, or environmental factor
  • Neuropathy, muscle weakness, arthropathy or other musculoskeletal diagnosis of the upper extremity that impairs dexterity or function
  • Has trauma to the nervous system within 3 months preceding the onset of tremor
  • Is unwilling or unable to refrain from drinking alcohol 24 hours before and during clinical study assessments, or regular use of alcohol that would preclude abstinence from alcohol for this time period around visits
  • Has trauma to the nervous system within 3 months preceding the onset of tremor
  • Has deep brain stimulator (DBS) that in the investigator's discretion is associated with significant stimulation side effects that could impact participant safety

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in United States

  • United BioSource LLCMorgantown, United StatesContact: Study Coordinator CenterTaking people

About the trial

What the trial wants to find out

The goal of this clinical study is to compare ulixacaltamide and placebo treatment in essential tremor. The main question it aims to answer is:

Read full original descriptionShow less

• Is ulixacaltamide a safe and efficacious treatment for patients with essential tremor?

Participants will be asked to participate in one of two clinical studies where they will be treated with either ulixacaltamide or placebo for a period of up to 12 weeks. After the controlled study completion, they will be eligible to participate in a long-term, open-label safety study (LTSS) and be treated with ulixacaltamide. Participants are eligible to enroll directly into the LTSS if they previously participated in an essential tremor trial, received sponsor invitation after being deemed ineligible for the controlled study, or following enrollment closure of the controlled study.

The 6 groups in the trial

  • Parallel Design: ulixacaltamide armTreatment being tested

    Double-blind Part: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, 70 days of 60 mg

    Treatment: 60 mg ulixacaltamide

  • Parallel Design: placebo armPlacebo, for comparison

    Double-blind Part: Oral dosing, once daily in the morning: 84 days of placebo

    Treatment: Placebo

  • Randomized WithdrawalTreatment being tested

    Double-blind Part: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, 42 days of 60 mg Randomized Withdrawal Part: Following double-blind part: 1:1 randomization to placebo or 60 mg ulixacaltamide for 28 days

    Treatment: 60 mg ulixacaltamide and Placebo

  • Long-term Safety Study: Essential1 rolloversTreatment being tested

    Open-label Part: Oral dosing, once daily in the morning up to 3 years 60 mg ulixacaltamide

    Treatment: 60 mg ulixacaltamide

  • Long-term Safety Study: Parallel Design and Randomized Withdrawal rolloversTreatment being tested

    Open-label Part for patients previously on placebo: Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, up to 3 years 60 mg ulixacaltamide Open-label Part for patients previously on 60 mg ulixacaltamide: Oral dosing, once daily in the morning up to 3 years 60 mg ulixacaltamide

    Treatment: 60 mg ulixacaltamide

  • Long-term Safety Study: Direct Enrollment to LTSS StudyTreatment being tested

    Oral dosing, once daily in the morning with titration over 14 days to 60 mg ulixacaltamide: 7 days of 20 mg, 7 days of 40 mg, up to 3 years 60 mg ulixacaltamide

    Treatment: 60 mg ulixacaltamide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 3, Decentralized, Randomized, Double-Blind, Placebo Controlled, Parallel Design, Randomized Withdrawal, and Long-term Safety Study to Evaluate the Efficacy and Safety of Ulixacaltamide (PRAX-944) in Adults With Essential Tremor
Plain-language title
Ulixacaltamide compared with placebo for essential tremor in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06087276, who can take part
Record updated
6 October 2026